These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23264925)

  • 1. Targeting MDSCs enhance therapeutic vaccination responses against lung cancer.
    Srivastava MK; Dubinett S; Sharma S
    Oncoimmunology; 2012 Dec; 1(9):1650-1651. PubMed ID: 23264925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma.
    Sato Y; Shimizu K; Shinga J; Hidaka M; Kawano F; Kakimi K; Yamasaki S; Asakura M; Fujii SI
    Oncoimmunology; 2015 Mar; 4(3):e995541. PubMed ID: 25949922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer.
    Srivastava MK; Zhu L; Harris-White M; Huang M; St John M; Lee JM; Salgia R; Cameron RB; Strieter R; Dubinett S; Sharma S
    Immunotargets Ther; 2012 Oct; 2012(1):7-12. PubMed ID: 24791250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
    Shariatpanahi SP; Shariatpanahi SP; Madjidzadeh K; Hassan M; Abedi-Valugerdi M
    J Theor Biol; 2018 Apr; 442():1-10. PubMed ID: 29337259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model.
    Shi G; Wang H; Zhuang X
    Oncol Lett; 2016 Jan; 11(1):809-816. PubMed ID: 26870289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells.
    Lim J; Lee A; Lee HG; Lim JS
    Biomol Ther (Seoul); 2020 Jan; 28(1):1-17. PubMed ID: 31431006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells.
    Shime H; Maruyama A; Yoshida S; Takeda Y; Matsumoto M; Seya T
    Oncoimmunology; 2017; 7(1):e1373231. PubMed ID: 29296526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
    Bruno A; Mortara L; Baci D; Noonan DM; Albini A
    Front Immunol; 2019; 10():771. PubMed ID: 31057536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders.
    Barnie PA; Zhang P; Lv H; Wang D; Su X; Su Z; Xu H
    Exp Ther Med; 2017 Feb; 13(2):378-388. PubMed ID: 28352304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
    Cekic C; Day YJ; Sag D; Linden J
    Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of low-dose fludarabine or 5-fluorouracil on the tumor growth and myeloid derived immunosuppression status of tumor-bearing mice.
    Abedi-Valugerdi M; Zheng W; Benkessou F; Zhao Y; Hassan M
    Int Immunopharmacol; 2017 Jun; 47():173-181. PubMed ID: 28411578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.
    Lu LC; Chang CJ; Hsu CH
    J Hepatocell Carcinoma; 2019; 6():71-84. PubMed ID: 31123667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.
    Nausch N; Galani IE; Schlecker E; Cerwenka A
    Blood; 2008 Nov; 112(10):4080-9. PubMed ID: 18753637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.
    Stiff A; Trikha P; Mundy-Bosse B; McMichael E; Mace TA; Benner B; Kendra K; Campbell A; Gautam S; Abood D; Landi I; Hsu V; Duggan M; Wesolowski R; Old M; Howard JH; Yu L; Stasik N; Olencki T; Muthusamy N; Tridandapani S; Byrd JC; Caligiuri M; Carson WE
    Clin Cancer Res; 2018 Apr; 24(8):1891-1904. PubMed ID: 29363526
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.
    Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
    Clin Cancer Res; 2014 Aug; 20(15):4096-106. PubMed ID: 24907113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
    Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
    Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.